
BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

# BioSpectrum Ranking Survey: Rank 7: AstraZeneca Pharma India

15 September 2016 | Features | By BioSpectrum Bureau

**BioSpectrum Ranking Survey: Rank 7: AstraZeneca Pharma India**




**AstraZeneca Pharma India**
**Total Revenue: Rs 570.5 crore**
**MD: Sanjay Murdeshwar**

Bangalore based AstraZeneca Pharma India's total revenue for FY 15-16 is Rs 5,705,049,408 (Rs 5705 million).

The company registered sales of Rs 5167.6 million with a growth of 11 percent achieving a Net Profit of Rs 53 million, during the year. The company's key growth brands - Brilinta, Forxiga, Onglyza, Kombiglyze and Symbicort, witnessed robust growth of 76 percent over last year, providing strong momentum to the company's performance throughout the year.

Diabetes portfolio of the company grew by 74 percent post acquisition from Bristol Myers-Squibb and launch of Forxiga. Forxiga is part of a newer class of medicines known as SGLT2 (Sodium Glucose Cotransporter 2) inhibitors that act to block reabsorption of sugar in the kidneys.

In addition, Brilinta won the OPPI Marketing Excellence Awards in the category of 'Best New Pharma Product Launch'. Brilinta also won the 'Brand of The Year' AWACS - AIOCD Award for Chronic category under 'Best New Pharma Product Launch'. The drug, Brilinta (Ticagrelor) which provides cardiologists with a new and effective treatment to help reduce the rate of heart attack and cardiovascular deaths in adult patients with Acute Coronary Syndrome (ACS).

Â

AstraZeneca Pharma India has entered into three Distribution Services Agreement in FY 2015-2016. With Dr Reddy's Laboratories for Saxagliptin and its fixed dose combination with metformin, its patented therapy for the treatment of type 2 diabetes.

The second Distribution Services Agreement is with Sun Pharma for Ticagrelor, treatment for acute coronary syndrome (ACS) and the third Distribution Services Agreement for the treatment of type 2 diabetes with Sun Pharma to promote and distribute Dapagliflozin and its fixed dose combination with metformin.

Pursuant to the above agreements, AstraZeneca Pharma India, Dr Reddy's Laboratories and Sun Pharma will co-promote, market & distribute Saxagliptin, Dapagliflozin and Ticagrelor under different brand name in Indian market.
These partnerships are in line with the firm's commitment to transform patient care in diabetes and ACS. The company believes it will enable them to increase the share of voice for the molecules through a wider reach to physicians, thereby benefitting more number of patients.

As of March 31, 2016, AstraZeneca India had 15,876 employees.

Â

Â